Melanomas are considered to be one of the most immunogenic cancers and are frequently infiltrated with CD8 + and CD4 + T lymphocytes specific for major tumor antigens. CD8 + cytotoxic T lymphocytes (CTL) mediate antigen-specific lysis of tumor cells through cytolytic granule proteins, such as granzymes, granulysin and perforin. Previously, other investigators have shown a lack of complete CTL differentiation in solid tumors. 1 However, the exact stage of differentiation affected was unclear. We recently reported in Clinical Cancer Research a novel subset of CD8 + tumor-infiltrating lymphocytes (TILs) that co-expressed early effector-memory markers (CD27 and CD28) and a marker for end-stage, senescent T cells (CD57 + T lymphocytes have also been observed in the peripheral blood of melanoma patients after vaccination with gp100 tumor antigen. 6 We set out to determine the role of CD8 + CD57 + T cells in the melanoma. By performing flow cytometry staining on TIL isolated from 44 metastatic tumors, we found that the CD8 + CD57 + subset was 16.2 ± 3.5% of the total tumor-infiltrating CD8 + T cells. The vast majority of these CD8 + T cells were also "locked" in the T EM stage and, on average, > 20% of the CD8 + CD57 + subset co-expressed CD27 and CD28. These T cells were GB hi but Perf lo/-, and they recognized melanoma tumor antigens, MART-1 and gp100 in HLA-A2 + patients. In contrast, only a few (< 5%) of the CD8 + CD57 + T cells in the PBMC of the same melanoma patients coexpressed CD27 and CD28, but they were GB hi and Perf hi . We also found a similar population in pleural effusions from metastatic breast cancer. Notably, this TIL subset was different from the Foxp3 + CD8 + early effector TILs, which did not express CD57, as reported earlier in reference 7.
Whether CD8 + CD57 + T cells are really "senescent" has become a controversial issue. 3 We addressed this issue in the CD8 + CD27 + CD57 + TIL subset and found that they indeed proliferated in response to IL-2. We then purified this subset from IL-2-cultured TILs by cell sorting. Interestingly, we found that the CD27 + CD57 + TILs were able to proliferate and produce high levels of IFNγ upon TCR stimulation, which was inconsistent with CD57 as a general marker for T-cell senescence. We also found that PD-1 expression was higher in the CD27 + CD57 + subset compared with the CD27 + CD57 -subset. Since CD8 + T cells naturally express PD-1 as a result of TCR activation, where it plays a regulatory mechanism to prevent over-reactivity, 3 it
Incomplete differentiation of CD8 + cytotoxic t-lymphocytes (CtLs) in the tumor microenvironment is associated with cancer progression. we describe a new type of tumor-infiltrating CD8 + CD57 + t cell in cancer with hybrid phenotypic and functional properties of both an early effector-memory cell and a terminally-differentiated effector cell. these cells behave as incompletely-differentiated CtLs.
at the CD27 + stage. Taken together, these findings may help explain why metastatic melanomas are often infiltrated with only early T EM CD8 + T cells that have limited ability to kill tumor cells. Thus, TGFβ1 may be a key suppressor of CTL differentiation in the tumor microenvironment (Fig. 1) . However, other factors such as PGE 2 , indoleamine-2,3-diooxygenase (IDO), IL-10, or inhibitory signaling through PD-1, may also play a role. (Fig. 1) . TCR-stimulation induced the differentiation of sorted CD8 + CD27 + CD57 -TILs into a Perf hi , CD27 -CD57 -subset, but the cells differentiating from the CD27 + CD57 + subset on average acquire higher perforin levels and killing function (Fig. 1) (Fig. 1) . IL-2 treatment alone induced a minor + t cells at a transitional stage where markers for early t eM (CD27, CD28) are co-expressed with CD57, even though the cells remain Perf lo . we also found that tGFβ1, an immunosuppressive cytokine frequently found in the microenvironment of metastatic cancer, could also contribute to the arrested differentiation and accumulation of CD27 + CD57 -precursor t cells and CD27 + CD57 + t cells. we found that PD-1 was expressed more in the CD27 + CD57 + t cells, which implied that they may exhibit a higher level of effector activity. when these tumor-infiltrating lymphocytes (tIL) are expanded with IL-2, a minor fraction (~30%) of CD27 + CD57 -subset differentiated into CD27 + CD57 + t cells. After tCr stimulation ex vivo, the CD27 + CD28 + CD57 -subset directly differentiated to become CD27 -CD57 -t cells. On the other hand, CD27 + CD57 + differentiated to become CD27 -CD57 + , and in some patients, CD27 -CD57 -. these phenotypic changes were accompanied by increased perforin expression and acquisition of potent cytotoxicity against tumor cells. we think that CD57 is not a marker for t-cell senescence, but rather marks highly differentiated t cells that are in the process of transitioning into a truly end-stage, effector CtL. Currently it is not known which set of markers define truly senescent, end-stage, highly cytolytic CtL. we also propose that ultimately, both the CD8 + CD57 + and CD8 + CD57 -subsets may ultimately differentiate into a subset of CD8 + CD27 -CD28 -CD57 -cells that may be more NK-like, expressing higher levels of CD122, KLrG1, NKG2D and other NK receptors.
In conclusion, we characterized a novel subset of TILs in metastatic melanoma and breast cancer that seems to be locked in a transitional state between early T EM and fully-differentiated CTL. Our study also underscores the need for a greater understanding of the state of CTL differentiation and activity in patients in relation to tumor control. Overall, there has been an over-emphasis on the role of cytokine release by CD8 + T cells (e. 
